/owareness @WCCNV
ABOUT US
PHYSICIANS
PRACTICE AREAS AND PROCEDURES
FOR PATIENTS
WCC FOUNDATION FOR RESEARCH
RESOURCE LIBRARY
OWARENESS
About Us
 
Letter from Director
Policies and Confidentialities
Research Department
Clinical Trials
/owareness @owareness
Clinical Trials

The Women's Cancer Center of Nevada Foundation for Research is a member of the Gynecologic Oncology Group (GOG), a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of their processes is utilized in order to constantly improve the quality of patient care.

Below is a partial list of current clinical trials with which the Women's Cancer Center is involved. To learn more, or to find other related studies, please visit the NIH Clinical Trials website which features a searchable database.
    Las Vegas Medical Marijuana Trials - What marijuana culture is or will become has been widely discussed by many. To one small group of doctors, though, that culture means little. For these doctors, their patients are the only ones who matter. » Learn more

    GOG-264 - A randomized phase II trial of Paclitaxel and carboplatin vs. bleomycin, etoposide and cisplatin for newly diagnosed advanced stage and recurrent chemo-na´ve sex cordstromal tumors of the ovary.

    GOG-3004 - A phase III, randomized, double blind, placebo controlled, multicenter study of Olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy.

    GOG-213 - A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary Cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer.

    GOG-260 - A phase II evaluation of Elesclomol Sodium and weekly paclitaxel in the treatment of recurrent or persistent-resistant ovarian, fallopian tube or primary peritoneal cancer.

    GOG-281 - A randomized phase II/III study to access the efficacy of Trametinib in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer.

    GOG-283 - A phase II trial of DCTD-sponsored Dasatinib in recurrent/persistent ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma characterized for the retention of loss of BAF250a expression.

    GOG-244 - The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors, and impact in newly diagnosed patients.

    GOG-258 - A randomized phase II trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel for optimally debulked, advanced endometrial cancer.

    GOG-275 - A phase III randomized trial of pulse actinomycin-D multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasia.

    GOG-277 - A phase III randomized trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for the uterus-limited, high grade uterine leiomyosarcoma.

    GOG-286B - A randomized phase II/III study of paclitaxel/carboplatin/Metformin vs Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVA, Stage IVB, or recurrent endometrial cancer.

    GOG-238 - A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

    GOG-283 - A phase II trial of DCTD-sponsored Dasatinib in recurrent/persistant ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma characterized for the retention of loss of BAF250a expression.

    GOG-286B - A randomized phase II/III study of paclitaxel/carboplatin/Metformin vs Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVA, Stage IVB, or recurrent endometrial cancer.

    GOG-237 - Comparative analysis of CA-IX, p16, proliferative markers, and human papilloma virus (HPV) in the diagnosis of significant cervical lesions in the patients with cytologic diagnosis of atypical glandular cells (AGC).

    GOG-244 - The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors and impact in newly diagnosed patients.

    GOG-263 - Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy.

    GOG-274 - A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: OUTBACK Trial (ANZGOG 0902).

    GOG-278 - Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic LNDX) for Stage IA1 (LVSI+) and IA2-IB1 (=2cm) cervical cancer.

    GOG-244/UMC 12.07.005 - The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors, and impact in newly diagnosed patients.

    GOG-270 - GROningen International Study on Sentinel nodes in vulvar cancer; An observational study.

    GOG-279/UMC 13.05.008 - A phase II trial evaluating cisplatin and gemcitabine concurrent with intensity-modulated radiation therapy (IMRT) in the treatment of locally advanced squamous cell carcinoma of the vulva.

    PR-1205 - A prospective, safety and efficacy cohort study of elevate anterior and apical prolapsed repair system compared to native tissue repair for pelvic organ prolapsed repair.

    PR-1206 - A prospective, safety and efficacy cohort study of elevate posterior and apical prolapsed repair system compared to native tissue repair for pelvic organ prolapsed repair.